Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dharmacon Inc.
Appointments: Amgen, Sirnaomics, Pandion, Purdue, Cardurion, OncoSec Make Senior Hires
Senior executives are to depart Gilead Sciences, Bristol-Myers Squibb and Amgen, while C-suite and board hires have been reported at Sirnaomics, Pandion, Purdue Pharma, Cardurion and OncoSec.
Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology
The lesson that entrepreneurs and VCs seem to be taking from the fast-paced ophthalmology sector is the need for shorter development time frames and clinical candidates with reduced risk. Among others, MacuSight, Danube, and Lux, profiled here, are to one extent or another revisiting the existing pharmacopeia to test ophthalmic indications for existing compounds.
Deal Statistics Quarterly, Q1 2004
Statistical review compiled from our Strategic Transactions database including financings by type (IPO, private placement etc.); financings by sector (surgical equipment, implantable devices, etc.); alliances by therapeutic category (cardiovascular, orthopedic, etc.); alliances by industry segment (biomaterials, monitoring equipment, etc. ); for three separate industries: medical devices, in vitro diagnostics, and pharmaceuticals/biotechnology.
Acuity Pharmaceuticals Inc.
Acuity Pharmaceuticals is developing VEGF-directed RNAi-based therapeutics for ophthalmic diseases, including age-related wet macular degeneration and diabetic retinopathy.
- Research, Analytical Equipment & Supplies
- Antisense, Oligonucleotides
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.